Navigation Links
Tengion to Present at the BIO CEO & Investor Conference
Date:2/5/2013

WINSTON-SALEM, N.C., Feb. 5, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis , Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City. 

A live audio webcast of the presentation can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2013/23210244.cfm or under "Calendar of Events" in the Investors & News section of the Company's website at www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product c
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Tengion Reports Second Quarter 2012 Financial Results
2. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
3. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
4. Regulus to Present at Two Upcoming Investor Conferences
5. Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
6. Epizyme to Present at Upcoming Conferences in February
7. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
8. Wacoms DTH-2242: An Ideal Interactive Pen and Touch Display Solution for Healthcare and Presentation Markets
9. Solta Medical to Present at the Leerink Swann Global Healthcare Conference in New York on February 14, 2013
10. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
11. Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES ... the pharmaceutical, biotechnology and medical device industries, today confirmed ... of Dr. Michael J. McKelvey, its President and CEO, ... currently ERT,s Chairman and Chief Scientific Officer, has also ...
... 21, 2010 PTC Therapeutics, Inc. announced today that ... trial of ataluren, an investigational new drug, in patients ... http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The 48-week study is designed to ... with nmCF.  The trial has enrolled 238 patients at ...
Cached Medicine Technology:ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 2ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 2PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 4
(Date:5/24/2013)... 2013 According to the National Institutes of ... epidermal necrolysis (TEN) that affects the skin and mucous membranes. ... under the age of 30 (i). In the early ... fever. As SJS advances, it affects the mucous membranes ... anus. Inflammation of the eye causes conjunctivitis (pink eye). ...
(Date:5/24/2013)... BEACH, CA (PRWEB) May 24, 2013 ... health care education community, proudly participated in festivities surrounding ... April 19-21. The event provided the perfect backdrop to ... facilities at 236 E. 3rd Street, housed in an ... Arts Building. , ACC was an active exhibitor throughout ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- About one in ... their teens take up smoking, drinking or illicit drug ... too bad, say experts at the Substance Abuse and ... that parents are actually one of the most influential ... issues. "Surveys of teens repeatedly show that ...
(Date:5/24/2013)... May 2013, Paris, France: Routinely measuring fractional flow ... angiography for diagnosis of chest pain leads to ... four patients, according to results from a study ... routine pressure wire assessment influence management strategy at ... was designed to assess whether routine assessment of ...
(Date:5/24/2013)... youth and diabetes keeps getting worse. The latest data from ... Type 2 diabetes are at high risk to develop heart, ... than people who acquire Type 2 diabetes as adults. ... to be at very high risk for early complications when ... endocrinology in the School of Medicine at The University of ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:American Career College Revs Up Community Support During Toyota Grand Prix of Long Beach 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2
... CHAPEL HILL, N.C., May 27 As the ... companies are looking,for ways to up-sell and cross-sell ... the need for such practices, Best Practices LLC ... from less than 5% of their,service calls., ...
... NY/LOS ANGELES, CA: Stand Up To Cancer ... philanthropic dollars for accelerating ground-breaking research, launches today ... networks, entertainment industry executives, celebrities and prominent leaders ... CBS and NBC will donate one hour of ...
... TUCSON, Ariz., May 27 Medipacs, Inc., a ... is has secured an,initial financial investment of $1.65 ... Venture Partners and other investors in Tucson, San,Diego, ... Mark McWilliams comments: "We are very pleased with,the ...
... IMTEC Corporation proudly,introduces a newly redesigned version ... works in conjunction with IMTEC,s proprietary,FlashCT(R) software for ... scanner, Vision provides users with tools for viewing, ... may be in the form of,a raw scan ...
... in Melanoma , Mutations in the p14ARF tumor ... independent of the effect of the p16 gene. , ... on chromosome 9 that is frequently mutated in melanomas. ... p16 tumor suppressor gene occurs frequently in melanomas, it ...
... days off, poor-quality output, study finds , , TUESDAY, May ... hyperactivity disorder (ADHD) miss, on average, more than three ... new global reckoning of the problem. , Altogether, between ... ADHD, according to survey data from the World Health ...
Cached Medicine News:Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 2Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 3Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 4Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 5Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 6Health News:IMTEC Introduces New Vision Software 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
... blood flow and minimize pain when ... safety-engineered BD Microtainer Quikheel Lancet. The ... blade providing a precise and consistent ... into its casing, helping to protect ...
The HEMOCHRON Signature Elite offers state-of-the-art features like barcode scanning, internal Electronic Quality Control (EQC), QC Lockout and alphanumeric data entry for Patient Identification (PID...
... Our highest throughput solution for ELISA testing. ... 2 Sample Processors, 1 Robot, and 1 ... solution automatically performs: dispensing of samples from ... plate transport via the robotic transport system ...
Medicine Products: